Musculoskeletal Pain – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Musculoskeletal Pain Emerging Therapy and TPP Insights

Thelansis’s “Musculoskeletal Pain Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Musculoskeletal Pain Overview

Musculoskeletal pain encompasses a broad range of conditions affecting muscles, joints, bones, and connective tissue, spanning acute injury-related pain to chronic conditions such as osteoarthritis and persistent low back pain, and it remains one of the most common reasons people seek medical care. Historically, more severe cases relied heavily on opioid medications, but growing awareness of risks tied to long-term opioid use has pushed prescribers and drug developers toward non-addictive alternatives, a shift that reached a meaningful milestone with the arrival of a new class of oral pain medicine that blocks pain signals at the peripheral nerve level rather than the brain, offering effectiveness comparable to opioids without their addictive potential. Beyond pharmacologic treatment, management increasingly follows a multimodal approach combining medication with physical therapy, movement-based rehabilitation, and attention to the psychological factors that shape how chronic pain is experienced, reflecting a broader understanding that persistent musculoskeletal pain often involves changes in how the nervous system processes signals rather than ongoing tissue damage alone.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)